Navigation Links
Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S.

MORRISTOWN, N.J., Dec. 1 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 150mg. Distribution of the product has commenced.

Bupropion Hydrochloride extended-release tablets (XL), available in 150 & 300mg strength, are the generic equivalent of Wellbutrin XL(R) for the treatment of major depressive disorder. Annual U.S. sales of brand and generic Wellbutrin XL(R) were US$1,481 million for the 12 months ending September 2008 according to IMS Health data.

Commenting on the new approval, Doug Boothe, CEO of Actavis in the United States said:

"Bupropion XL 150mg, together with 300mg which was launched in August this year, offers significant value to our customers and patients. This approval also underscores Actavis' emphasis and capability in bringing complex controlled-release products to the marketplace."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
2. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
3. Actavis Extends Portfolio With Four New Products in the U.S.
4. Actavis Confirms its Patent Challenge of Kings Avinza(R)
5. Actavis Launches Amlodipine Tablets in the U.S.
6. Actavis Launches Carvedilol Tablets in the U.S.
7. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
8. EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery
9. Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award
10. ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications
11. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... Finnleo, a leader ... Eve on several models of traditional and far-infrared saunas. , For traditional ... is the most traditional Finnish sauna wood, and Finnleo uses only European Grade A ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at ... hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety ... fuller hair, without the need for surgery, prescription pills, or topical foams. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating half ... ” campaign. The partnership between the two groups began in 2014 with Vitalalert pledging ... , MAP International was founded in 1954 and is an international Christian-based health organization ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to ... are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses ... , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. ...
(Date:11/25/2015)... Crystal Lake, IL (PRWEB) , ... November 25, 2015 , ... ... pleased to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto ... the case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... WASHINGTON , Nov. 25, 2015  The ... Obstetricians and Gynecologists (ACOG), and the March of ... bipartisan Protecting Our Infants Act of 2015 ... the number of newborns born exposed to drugs, ... Since the bill,s introduction, all three organizations have ...
Breaking Medicine Technology: